Crossmark

Antibiotics May be Safely Discontinued Within One Week of Percutaneous Cholecystostomy

Crossref DOI link: https://doi.org/10.1007/s00268-016-3861-y

Published Online: 2017-01-03

Published Print: 2017-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Loftus, Tyler J.

Brakenridge, Scott C.

Dessaigne, Camille G.

Sarosi, George A. Jr.

Zingarelli, William J.

Moore, Frederick A.

Jordan, Janeen R.

Croft, Chasen A.

Smith, R. Stephen

Efron, Phillip A.

Mohr, Alicia M.
Funding

Funding for this research was provided by:

National Center for Advancing Translational Sciences (UL1TR001427)

National Institute of General Medical Sciences (P50 GM111152–01, R01 GM105893‐01, R01 GM113945‐01, T32 GM‐08721)

National Center for Advancing Translational Sciences (UL1TR001427)

National Institute of General Medical Sciences (P50 GM111152–01, R01 GM105893-01, R01 GM113945-01, T32 GM-08721)
License Information

Version of Record valid from 2017-01-03

Text and Data Mining valid from 2017-01-03

Version of Record valid from 2017-01-03
More Information

Article History

First Online: 3 January 2017